Topic: The Lancet
In men receiving hormone therapy for prostate cancer, medroxyprogesterone should become the new standard treatment for preventing hot flushes, according to a study published online Dec. 7 in The Lancet Oncology.. Jacques Irani, M.D., of University Hospital in Poitiers, France, and colleagues ...
A large study of tibolone, a drug used to treat menopausal symptoms and to prevent osteoporosis, was halted early after researchers found that the synthetic steroid significantly increased the risk of recurrent breast cancer among survivors of the disease.. Tibolone, brand name ...
A synthetic steroid used to treat menopause symptoms and prevent osteoporosis significantly increases the risk of a relapse in breast cancer patients, according to a study released Tuesday.The steroid, called tibolone, should not be prescribed to a woman who has had or ...
A large study of tibolone, a drug used to treat menopausal symptoms and to prevent osteoporosis, was halted early after researchers found that the synthetic steroid significantly increased the risk of recurrent breast cancer among survivors of the disease.. Tibolone isn't available ...
MONDAY, Sept. 29 (HealthDay News) -- A model based on tumor characteristics after endocrine therapy can predict survival in women with breast cancer and help individualize treatment, according to a report published in the Oct. 1 issue of the Journal of the ...
Performing stellate-ganglion block to interrupt the sympathetic nervous system pathways regulating temperature reduces the frequency of severe hot flashes and sleep disturbances in breast cancer survivors, according to a report published online May 15 in The Lancet Oncology.. Eugene G. Lipov, M.D., ...
